New drug tested for patients with Treatment-Resistant transplant complication
NCT ID NCT07138196
Summary
This early-stage study is testing a new drug called Q702 in patients with chronic graft-versus-host disease that hasn't improved with standard treatments. The research aims to find the safest dose and understand how the drug works in the body. Participants will have moderate to severe symptoms from this transplant complication and will continue their current immune-suppressing medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Spain
-
Hospital Clinic de Barcelona
RECRUITINGBarcelona, Spain
-
Hospital General Universitario Gregorio Maranon
RECRUITINGMadrid, Spain
-
Hospital Universitario Marques de Valdecilla
RECRUITINGSantander, Spain
-
Hospital Universitario Puerta de Hierro Majadahonda
RECRUITINGMajadahonda, Spain
-
Hospital Universitario Virgen de la Arrixaca
RECRUITINGMurcia, Spain
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, Spain
-
Instituto de Investigacion Sanitaria
RECRUITINGValencia, Spain
Conditions
Explore the condition pages connected to this study.